![Elisa Petris](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Elisa Petris
Director/Miembro de la Junta en Quell Therapeutics Ltd. .
Cargos activos de Elisa Petris
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Syncona Partners LLP
![]() Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Inversor de Capital Privado | 01/01/2013 | - |
Blue Earth Diagnostics Ltd.
![]() Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Director/Miembro de la Junta | - | - |
Quell Therapeutics Ltd.
![]() Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | 19/03/2019 | - |
Achilles Therapeutics UK Ltd.
![]() Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/05/2016 | - |
Historial de carrera de Elisa Petris
Antiguos cargos conocidos de Elisa Petris.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Director/Miembro de la Junta | 06/10/2020 | - |
Formación de Elisa Petris.
Imperial College London | Doctorate Degree |
London Business School | Undergraduate Degree |
Estadísticas
Internacional
Reino Unido | 7 |
Estados Unidos | 2 |
Operativa
Director/Board Member | 3 |
Doctorate Degree | 2 |
Private Equity Investor | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
![]() | Health Technology |
Empresas privadas | 4 |
---|---|
Syncona Partners LLP
![]() Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Blue Earth Diagnostics Ltd.
![]() Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Health Services |
Quell Therapeutics Ltd.
![]() Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Elisa Petris
- Experiencia